Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
Introduction: the clear cell renal cell carcinoma (CRCC) is the most common cancer of the kidney, at the time of diagnosis 30% of patients have metastases and 40% are in disease recurrence. It is highly resistant to chemotherapy and poor responses were evidenced with the interleukins and interferon before use, so that the current target therapy with tyrosine kinase inhibitors were used. The objective of this study is to determine the survival and time to progression in patients with metastatic CRCC treated with Sunitinib. Materials and methods: retrospective study by Kaplan Meier technique, using the statistical package Epi Info 3.5, in patients with metastatic CRCC evaluated in the oncology department in the period between january 2010 and december 2012. Results: 42 patients with CRCC clear cell were analyzed, 22 of them were treated with Sunitinib and 20 did not receive this treatment. Findings show that the median survival for the group of patients treated with Sunitinib was 16 months versus 4.5 months for patients who did not. The median time to progression in the Sunitinib was 6 months. Conclusions: the results of the analysis of time of progression in patients treated with Sunitinib were similar at baseline and according to international oncology management guidelines. Favorable results were obtained in terms of survival; however results still are inconclusive.
REFENCIAS BIBLIOGRÁFICAS
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
American Cancer Society: Cancer Facts and Figures 2012.
Atlanta GACS, 2012. Avaible at: www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf
Karumanchi SA, Merchan J and Sukhatme VP. Renal cancer molecular mechanism and newer therapeutic options. Curr Opin Nephrol Hypertens 2012;11:37-42. Avaible at: www.ncbi.nlm. nih.gov/pubmed/11753085
Fisher RI, Rosenberg SA, Fyfe G. Long term survival update for high dose recombinant interleukin 2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6:Suppl 1:S55-S57
McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high dose interleukin 2 versus subcutaneous interleukin 2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-141[Erratum, J Clin Oncol 2005;23:2877.]
Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90
Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia inducible factors for oxygen dependent proteolysis. Nature 1999;399:271-275
NCCN Guidelines Version 1.2013 Kidney Cancer. Avaible at: www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
Heng DY, Xie W, Harschman LC, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor targeted agents: results from a large, multicenter study. J Clin Oncol. 2009
Dec 1;27(34):5794-5799. Avaible at: www.ncbi.nlm.nih.gov/pubmed/19826129
Flaningan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastasic renal cancer: a
combined analysis. J Urol2004;171:1071-1076. Avaible at: http://www.ncbi.nlm.nih.gov/pubmed/14767273
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus Interferon in metastatic renal cell carcinoma. N Engl J Med 2007; 358:115-124.
Avaible at: www.ncbi.nlm.nih.gov/pubmed/17215529
Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524
Motzer RJ, HutsonTE, Tomczac P, et al. Overall survival and uptdate results for Sunitinib compared with interferón alga in patientes with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-3590.
Avaible at: http://www.ncbi.nlm.nih.gov/pubmed/19487381
Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitarged inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol
;24:16-24.
Avaible at: http://www.ncbi.nlm.nih.gov/pubmed/16330672
Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high dose and low dose interleukin 2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-3132
Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337
Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-841
Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin 2, recombinant human interferón alfa 2a, or both in metastatic renal cell carcinoma. Groupe Francais d¨inmunetherapie. N Engl J Med 1998;338: 1272-1278. Avaible at: http://www.ncbi.nlm.nih.gov/pubmed/9562581
Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane
Database Syst Rev 2005;1:CD001425-CD001425 Medline
Heng DYC, Xie W, Harshman LC, et al. Externanl validation of International Metastasic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy (abstract). J Clin Oncol 2011; 29(15_suppl): Abstract 4560
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.